LuMend expands CTO (chronic total occlusions) catheter use in the US:
This article was originally published in Clinica
Executive Summary
LuMend has received US clearance to expand the market for its catheter for crossing chronic total occlusions (CTOs) from use in the just coronary vessels to use in the peripheral vasculature. The Frontrunner CTO catheter, claimed to be the only device specifically approved for both types of vessels, features controlled, blunt micro-dissection that gently separates atherosclerotic plaque, creating a passage through the CTO. It can move through longer peripheral CTOs in a "more expeditious manner" than standard guidewire techniques, said the Redwood City, California firm.